Summary
The aim of this proof of concept is to develop novel therapies based on the discoveries made during the AdvERC grant on mucus and mucins in the lung and intestine. The discovery that the XX protein is absent or almost absent in healthy individuals and animals and heavily increased in human COPD and induced lung disease in animals made us study this. During the ERC grant we discoverd that XX is anchoring and attaching the lung mucus by forming a cap on the accumulated mucus. In the absence of XX the mucus is non-attached and transported even better than normal. We have now determined the detailed molecular structure of the XX and learnt how this protein can form long, large polymers by non-covalent interactions. We will now develop inhibitory peptides, proteins, antibodies or small organic molecules to be used as therapeutic drugs for detaching the attached mucus at Cystic Fibrosis, Chronic bronchitis, COPD, and other lung diseases with mucus accumulation.
Unfold all
/
Fold all
More information & hyperlinks
| Web resources: | https://cordis.europa.eu/project/id/101100663 |
| Start date: | 01-03-2023 |
| End date: | 31-08-2024 |
| Total budget - Public funding: | - 150 000,00 Euro |
Cordis data
Original description
The aim of this proof of concept is to develop novel therapies based on the discoveries made during the AdvERC grant on mucus and mucins in the lung and intestine. The discovery that the XX protein is absent or almost absent in healthy individuals and animals and heavily increased in human COPD and induced lung disease in animals made us study this. During the ERC grant we discoverd that XX is anchoring and attaching the lung mucus by forming a cap on the accumulated mucus. In the absence of XX the mucus is non-attached and transported even better than normal. We have now determined the detailed molecular structure of the XX and learnt how this protein can form long, large polymers by non-covalent interactions. We will now develop inhibitory peptides, proteins, antibodies or small organic molecules to be used as therapeutic drugs for detaching the attached mucus at Cystic Fibrosis, Chronic bronchitis, COPD, and other lung diseases with mucus accumulation.Status
CLOSEDCall topic
ERC-2022-POC2Update Date
09-02-2023
Geographical location(s)
Structured mapping
